Nearly 92 percent of patients severely ill and hospitalized with coronavirus were discharged after they were treated with an antibody drug, new data reveals. Lenzilumab is an antibody drug developed to treat inflammation and immune over-response like that seen in coronavirus patients. Mayo Clinic's tests, though in their early stages, suggest that the drug could be life-saving for some of the sickest coronavirus patients. Most of the patients in the study needed non-invasive oxygen support, and several were on ventilators, a stage of COVID-19 with high death rates. None one of the small group of patients developed side effects from the antibody drug.

Source: Daily Mail June 15, 2020 18:35 UTC